Gene therapy

Politics Sarah Owermohle

STAT Plus: Official: FDA needs staff influx to meet gene therapy needs

Biotech Jason Mast

STAT Plus: How sickle cell became the first disease treated by CRISPR

First Opinion Richard Burr

STAT Plus: The FDA is at a crossroads on cell and gene therapies

The Readout Damian Garde

STAT Plus: Gene editing has had a big week in the spotlight. Here’s what’s going on

First Opinion Vivian G. Cheung

STAT Plus: How the government can help lower the price — not just the cost — of cutting-edge gene therapies

Biotech Jonathan Wosen

STAT Plus: Cell and gene therapy CEOs share survival strategies amid biotech slump

Biotech Jason Mast

STAT Plus: Taysha Gene Therapies’ plan to tackle rare diseases is crumbling

Biotech Jason Mast

STAT Plus: Gene therapy death was caused by an unknown risk of the virus used, study suggests

Biotech Jonathan Saltzman — Boston Globe

STAT Plus: Thermo Fisher just opened a $180 million plant. Executives already are talking about expanding.

In the Lab Jason Mast

STAT Plus: They carry a gene for ALS but aren’t sick. What does medical research owe them?

Hospitals Tara Bannow

STAT Plus: Dana-Farber deal highlights a surprising trend: New cancer centers are in vogue

Biotech Jason Mast

STAT Plus: AstraZeneca bets that gene therapy’s workhorse will still deliver the goods

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Racing for gene therapy, a pioneering approval, & startups in the lurch

Biotech Jason Mast

STAT Plus: With an age cutoff for a new gene therapy, families and doctors scramble to treat kids before their 6th birthday

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Biotech Jason Mast

STAT Plus: Gene therapy is in crisis. For nine hours, the field’s leading minds looked for a solution

Biotech Jason Mast

STAT Plus: AstraZeneca buys early-stage gene therapies from Pfizer in boon for struggling field

First Opinion Podcast Torie Bosch

Listen: One Duchenne patient’s bittersweet hope for new treatment

Biotech Adam Feuerstein

STAT Plus: BioMarin wins approval for gene therapy to treat hemophilia A

Biotech Jason Mast

STAT Plus: After promising early data, gene therapy trial for Huntington’s takes puzzling turn

Biotech Jason Mast

STAT Plus: After gene therapy deaths, Astellas brings in potentially safer treatment for muscle disorder

Biotech Megan Molteni

STAT Plus: In its first tough test, CRISPR epigenome editing cuts cholesterol levels in monkeys

Politics John Wilkerson

STAT Plus: FDA official offers insights into whether gene therapy makers could use common manufacturing process

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: The FTC v. Amgen, Sarepta’s future, & Galapagos’ turnaround

Politics Sarah Owermohle and Brittany Trang

STAT Plus: New Biden science agency ARPA-H launches first program, targeting bone regrowth

Biotech Jason Mast

STAT Plus: A new startup looks to turn the workhorse of gene therapy against cancer

Politics John Wilkerson

STAT Plus: FDA’s Califf talks cell and gene therapies, abortion pill, Alzheimer’s drugs

The Readout LOUD Damian Garde and Meg Tirrell

Listen: Bancel v. Bernie, Sarepta’s FDA runaround, & Regeneron’s ever-growing blockbuster

Biotech Matthew Herper

STAT Plus: Uniqure’s Huntington’s gene therapy lowers key protein in small trial